United States Patent 8,481,546: Gene Therapy for Cystic Fibrosis
US Patent 8,481,546, granted on July 9, 2013, to The Board of Trustees of the Leland Stanford Junior University, covers gene therapy methods for treating cystic fibrosis (CF). The patent claims encompass specific viral vectors, compositions, and methods for delivering corrected cystic fibrosis transmembrane conductance regulator (CFTR) genes to patient cells.
What is the core invention of Patent 8,481,546?
The primary invention detailed in US Patent 8,481,546 is a method of treating cystic fibrosis by introducing a functional CFTR gene into a patient's cells using a specific viral vector system. The patent aims to correct the underlying genetic defect responsible for CF.
What specific gene therapy components are claimed?
The patent claims several key components of the gene therapy system. These include:
- Viral Vectors: The invention specifically claims the use of adenoviral vectors. These vectors are modified to carry a nucleic acid sequence encoding a functional human CFTR protein. The adenoviral vectors are described as being replication-deficient, meaning they cannot replicate within the host cells, thereby reducing the risk of adverse events.
- Compositions: The patent also covers pharmaceutical compositions comprising these adenoviral vectors. These compositions are formulated for administration to patients and include the vector along with pharmaceutically acceptable carriers or diluents.
- Nucleic Acid Sequences: Claims extend to the nucleic acid sequence itself encoding the functional human CFTR protein, intended for delivery via the viral vector.
- Methods of Treatment: The core method claimed involves administering a therapeutically effective amount of the adenoviral vector composition to a subject suffering from cystic fibrosis. The goal is to achieve expression of the functional CFTR protein in the subject's cells, thereby ameliorating CF symptoms.
What is the claimed mechanism of action?
The claimed mechanism of action relies on the viral vector's ability to transduce, or deliver genetic material into, patient cells. Once inside the cells, the adenoviral vector releases the functional CFTR gene. This gene is then transcribed and translated, leading to the production of a normal CFTR protein. The functional CFTR protein restores the proper transport of chloride ions and water across cell membranes, addressing the fundamental defect in cystic fibrosis. The patent specifies targeting lung epithelial cells, as these are critically affected by CF.
What specific cystic fibrosis gene sequences are covered?
The patent claims the delivery of a nucleic acid sequence encoding a functional human CFTR protein. While it does not claim specific mutations of the CFTR gene that are corrected, it broadly covers the restoration of CFTR function by delivering a functional copy of the gene. The patent references GenBank accession numbers for the CFTR gene to define the target sequence. For instance, it implicitly references the full-length human CFTR cDNA.
What are the key claims of US Patent 8,481,546?
The patent contains multiple independent and dependent claims, outlining the scope of protection. Key claims include:
- Claim 1: A replication-deficient adenoviral vector comprising a nucleic acid sequence encoding a functional human cystic fibrosis transmembrane conductance regulator (CFTR) protein.
- Claim 12: A pharmaceutical composition comprising the adenoviral vector of claim 1 and a pharmaceutically acceptable carrier.
- Claim 23: A method for treating cystic fibrosis in a subject, comprising administering a therapeutically effective amount of the adenoviral vector of claim 1 to the subject.
- Claim 28: A method for increasing the expression of a functional CFTR protein in a subject’s airway epithelial cells, comprising administering to the subject a therapeutically effective amount of an adenoviral vector comprising a nucleic acid sequence encoding a functional human CFTR protein.
These claims highlight the protection of the vector itself, the therapeutic composition, and the method of using these components to treat cystic fibrosis.
What is the status of Patent 8,481,546?
US Patent 8,481,546 was granted on July 9, 2013. As of current data, the patent is expired. The term of a US patent is generally 20 years from the date of filing the application, subject to adjustments. The application for this patent was filed on February 27, 2004, making its projected expiration date February 27, 2024. Therefore, the patent is no longer in force.
What is the patent landscape surrounding this technology?
The patent landscape for cystic fibrosis gene therapy is dynamic, with numerous patents covering various aspects of vector technology, delivery methods, and specific gene constructs. While US Patent 8,481,546 focused on adenoviral vectors for CFTR gene delivery, subsequent research and patent filings have explored other viral vectors (e.g., lentiviral, adeno-associated viral) and non-viral delivery systems.
Patents in this field often claim:
- Specific viral serotypes and engineered variants for improved tropism and reduced immunogenicity.
- Novel vector designs that enhance transgene expression and duration of effect.
- Delivery formulations and devices optimized for pulmonary administration.
- Methods for ex vivo gene modification of patient cells, followed by transplantation.
- Combinatorial therapies involving gene therapy with other CF treatments.
- Specific CFTR gene sequences or modified versions designed for enhanced efficacy or to target particular mutations.
Companies and academic institutions actively patent their advancements in this area, creating a complex web of intellectual property that potential developers of new gene therapies must navigate. The expiration of foundational patents like 8,481,546 can open up licensing opportunities or enable generic development, depending on the remaining patent landscape for specific technologies.
Who are the key entities involved with this patent?
The assignee of US Patent 8,481,546 is The Board of Trustees of the Leland Stanford Junior University. This indicates that the invention originated from research conducted at Stanford University. The inventors listed on the patent are primarily academic researchers who developed the technology.
What are the implications of this patent's expiration?
The expiration of US Patent 8,481,546 has several implications:
- Freedom to Operate: The expiration removes a significant intellectual property barrier for companies and researchers looking to develop or utilize adenoviral vector-based gene therapies for cystic fibrosis, specifically using the broad claims of this patent.
- Potential for Generic Development: While gene therapy development is complex and expensive, the expiration could, in theory, pave the way for the development of generic versions of such therapies if specific formulations and manufacturing processes are not covered by other active patents.
- Further Research and Development: Researchers are no longer restricted by this patent's claims when exploring adenoviral vector technologies for CF. This can foster further innovation and the development of improved or alternative gene therapy approaches.
- Historical Significance: The patent represents an early step in the academic development of gene therapy for cystic fibrosis, contributing to the foundational knowledge in the field.
However, it is crucial to note that the broader landscape of cystic fibrosis gene therapy may still be protected by other active patents covering specific aspects of vector engineering, delivery, or therapeutic approaches.
What are the key technical challenges in adenoviral gene therapy for CF?
Despite its promise, adenoviral gene therapy for CF faces several technical hurdles that have been subjects of ongoing research:
- Immunogenicity: Adenoviruses are naturally occurring viruses that elicit a strong immune response in humans. Repeated administration of adenoviral vectors can lead to the development of neutralizing antibodies, which can reduce the vector's efficiency and cause inflammatory side effects. This has been a major challenge for sustained gene expression in the lungs.
- Transient Gene Expression: Adenoviral vectors typically do not integrate into the host genome. Therefore, the delivered gene is not permanently incorporated into the patient's DNA. As a result, the expression of the functional CFTR protein is often transient, requiring repeated administrations of the gene therapy.
- Delivery Efficiency: Achieving efficient and widespread delivery of the vector to the target cells in the lungs remains a challenge. Factors such as mucus barriers, clearance mechanisms, and the physical properties of the vector can limit transduction efficiency.
- Cytotoxicity: High doses of adenoviral vectors can exhibit some degree of cytotoxicity, potentially leading to inflammation and damage to lung tissue.
- Manufacturing and Scalability: Large-scale, high-quality manufacturing of clinical-grade adenoviral vectors is complex and costly. Ensuring consistent product quality and scalability for widespread therapeutic use is a significant undertaking.
- Off-target effects: While replication-deficient, there is always a concern for potential integration into the host genome in rare cases or for triggering unintended cellular responses.
These challenges have driven research towards developing next-generation adenoviral vectors with reduced immunogenicity, improved tropism, and enhanced transgene expression, as well as exploring alternative vector systems.
How does this patent relate to current CFTR modulator therapies?
US Patent 8,481,546 pertains to gene therapy, which aims to correct the underlying genetic defect by introducing a functional CFTR gene. In contrast, current leading treatments for cystic fibrosis, such as ivacaftor, lumacaftor, tezacaftor, and elexacaftor, are CFTR modulator therapies.
These modulator therapies do not introduce a new gene. Instead, they work by:
- Potentiators (e.g., ivacaftor): These drugs help the CFTR protein channel to stay open longer, allowing more chloride ions to pass through. This is effective for individuals with certain gating mutations.
- Correctors (e.g., lumacaftor, tezacaftor, elexacaftor): These drugs help the misfolded CFTR protein to fold correctly, reach the cell surface, and function more effectively. This is particularly beneficial for individuals with processing mutations.
While gene therapy and CFTR modulator therapies share the ultimate goal of restoring CFTR function, their mechanisms of action are fundamentally different. The expiration of patents like 8,481,546 is relevant to the development of gene-based treatments, while the landscape for modulator therapies is governed by a separate set of patents related to small molecule chemistry, drug formulations, and specific therapeutic regimens. The development of combination modulator therapies represents a significant advancement that addresses a broader range of CFTR mutations than was initially feasible with early gene therapy approaches.
Key Takeaways
- US Patent 8,481,546, granted to Stanford University, claimed adenoviral vector-based gene therapy for cystic fibrosis.
- The patent protected specific adenoviral vectors, compositions, and methods for delivering functional CFTR genes.
- The patent expired on February 27, 2024, removing an IP barrier for adenoviral vector research and development for CF.
- Key technical challenges in adenoviral gene therapy include immunogenicity, transient expression, and delivery efficiency.
- Current leading cystic fibrosis treatments are CFTR modulator therapies, distinct from gene therapy mechanisms.
Frequently Asked Questions
-
Can I now freely use the technology described in US Patent 8,481,546?
The core claims of US Patent 8,481,546 have expired. However, other patents may exist that cover specific aspects of adenoviral vector technology, CFTR gene constructs, or therapeutic applications that could still be in force. A thorough freedom-to-operate analysis is required.
-
Does the expiration of this patent mean a cure for cystic fibrosis is imminent?
The expiration of this patent allows for further development and research in adenoviral gene therapy for CF. However, significant technical challenges remain for gene therapy to become a widespread clinical treatment for CF, and its success does not guarantee an immediate cure.
-
Were there any specific CFTR gene mutations targeted by this patent?
The patent generally claims the delivery of a nucleic acid sequence encoding a "functional human CFTR protein." It does not specifically claim correction of particular CFTR mutations but rather the restoration of CFTR function through gene delivery.
-
What are the advantages of adenoviral vectors claimed in this patent over other viral vectors?
The patent emphasizes the use of replication-deficient adenoviral vectors, which were seen as advantageous for their ability to deliver genetic material efficiently and with reduced risk of uncontrolled replication compared to some earlier viral vector designs. However, adenoviruses are known for inducing immune responses.
-
How does gene therapy, as described in this patent, differ from current small molecule CFTR modulator drugs?
This patent describes gene therapy, which aims to introduce a correct copy of the CFTR gene into a patient's cells to address the genetic root cause of CF. Current CFTR modulator drugs, in contrast, are small molecules that help existing, albeit defective, CFTR proteins function more effectively without introducing new genetic material.
Citations
[1] The Board of Trustees of the Leland Stanford Junior University. (2013). United States Patent 8,481,546: Gene therapy for cystic fibrosis. U.S. Patent and Trademark Office.
